Finen 20 mg (Tablet)
Unit Price: ৳ 110.00 (1 x 10: ৳ 1,100.00)
Strip Price: ৳ 1,100.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Finerenone |
| Company | General pharmaceuticals ltd |
| Also available as |
Indications
- reduce the risk of sustained eGFR decline
- reduce the risk of end-stage kidney disease
- reduce the risk of cardiovascular death
- reduce the risk of nonfatal myocardial infarction
- reduce the risk of hospitalization for heart failure
- indicated for adult patients with chronic kidney disease associated with type 2 diabetes
Pharmacology
- nonsteroidal
- selective antagonist of the mineralocorticoid receptor (MR)
- blocks MR mediated sodium reabsorption
- blocks MR overactivation in epithelial and nonepithelial tissues
- thought to contribute to fibrosis and inflammation
- high potency and selectivity for the MR
- no relevant affinity for androgen, progesterone, estrogen, and glucocorticoid receptors
- decreases mean systolic blood pressure by 3 mmHg
- decreases mean diastolic blood pressure by 1-2 mmHg
- complete absorption after oral administration
- metabolism resulting in absolute bioavailability of 44%
- Cmax achieved between 0.5 and 1.25 hours after dosing
- exposure increases proportionally over a dose range of 1.25 to 80 mg
- steady state achieved after 2 days of dosing
- plasma protein binding of finerenone is 92%
- primarily metabolized by CYP3A4 and CYP2C8
- about 80% of the administered dose is excreted in the urine
Dosage & Administration
- recommended starting dosage of 10 mg or 20 mg orally once daily
- increase dosage after 4 weeks to the target dose of 20 mg once daily
- tablets may be taken with or without food
- recommended dosage based on eGFR: eGFR ≥60 mL/min/1.73 m2 - starting dose 20 mg once daily, eGFR ≥25 to <60 mL/min/1.73 m2 - starting dose 10 mg once daily, eGFR <25 mL/min/1.73 m2 - not recommended
- for patients who are unable to swallow whole tablets, can be crushed and mixed with water or soft foods
- monitor serum potassium 4 weeks after initiating treatment and adjust dose if necessary
- instruct patients on missed dose management
Interaction
- contraindicated with strong CYP3A4 inhibitors
- moderate and weak CYP3A4 inhibitors increase exposure
- monitor serum potassium with moderate or weak CYP3A4 inhibitors
- avoid concomitant use with strong or moderate CYP3A4 inducers
Contraindications
- concomitant use with strong CYP3A4 inhibitors
- patients with adrenal insufficiency
Side Effects
- hyperkalemia
- hypotension
- hyponatremia
Pregnancy & Lactation
- no available data on use in pregnancy
- animal studies show developmental toxicity at high exposures
- avoid breastfeeding during treatment and for 1 day after treatment
Precautions & Warnings
- can cause hyperkalemia
- risk increases with decreasing kidney function and higher baseline potassium levels
- more frequent monitoring may be necessary for patients at risk for hyperkalemia
Use in Special Populations
- safety and efficacy not established in patients below 18 years of age
- no overall differences in safety or efficacy observed in elderly patients
- avoid use in patients with severe hepatic impairment
- consider additional serum potassium monitoring in patients with moderate hepatic impairment
Overdose Effects
- suspected overdose: immediately interrupt treatment
- most likely manifestation is hyperkalemia
- standard treatment for hyperkalemia should be initiated
Therapeutic Class
- mineralocorticoid receptor antagonists
Storage Conditions
- keep below 30°C
- keep away from light and moisture
- keep out of the reach of children